In our prospective , randomised , double-blind , placebo-controlled , parallel-group study , we enrolled patients aged 40-80 years with moderate-to-severe COPD ( post-bronchodilator forced expiratory volume in 1 s [ FEV1 ] / forced vital capacity < 07 and FEV1 of 30-70 % of predicted ) at 34 hospitals in China .